Astonea Labs FY26 Revenue Up, Profit Down; Diversifies Into Nutraceuticals

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Astonea Labs FY26 Revenue Up, Profit Down; Diversifies Into Nutraceuticals

Astonea Labs reported a 51% revenue jump in FY26 to ₹147.58 crore, but profit fell to ₹4.52 crore from ₹5.35 crore. The company is diversifying into nutraceuticals and ayurvedic products.

Detailed Coverage

Astonea Labs Reports Robust Revenue Growth but Lower Profit in FY26

Revenue in FY26 reached ₹147.58 crore, a significant increase from ₹97.52 crore in FY25.
Profit for FY26 declined to ₹4.52 crore from ₹5.35 crore in the previous year.

Reader Takeaway: Strong topline growth driven by diversification plans faces pressure from reduced profitability post-fire incident.

What just happened

Astonea Labs Ltd. announced its audited consolidated financial results for the fiscal year ended March 31, 2026. The company reported a substantial increase in revenue to ₹147.58 crore, up from ₹97.52 crore in the previous fiscal year. However, the net profit saw a decline, falling to ₹4.52 crore from ₹5.35 crore in FY25. Consequently, the basic Earnings Per Share (EPS) decreased from ₹6.94 to ₹4.49.

Why this matters

The revenue growth indicates successful market expansion or increased sales volume. However, the dip in profitability despite higher revenues suggests potential cost pressures or one-off expenses. The company is also strategically diversifying into nutraceuticals and ayurvedic products, which could be a future growth driver. Investors will be watching how the company manages costs and integrates new product lines.

The backstory

In FY25, Astonea Labs had reported a revenue of ₹97.52 crore and a profit of ₹5.35 crore. The current fiscal year shows significant topline expansion but a contraction in the bottom line. The company has also faced an operational hazard with a fire incident causing an estimated loss of ₹9.39 crore.

What changes now

The Board has approved changes to the company's Memorandum of Association to enable business in pharmaceuticals, nutraceuticals, ayurvedic products, and dietary supplements. New subsidiary companies are planned for India to focus operations and explore opportunities. Furthermore, the termination of supply and distribution agreements with Astonea One Private Limited has been deferred, keeping those agreements active.

Risks to watch

A major fire incident on April 27, 2026, damaged the factory, leading to an estimated loss of ₹9.39 crore. This poses a risk to production capacity and may impact the company's financial recovery, insurance claims, and overall profitability. Investors should closely monitor the resolution of insurance claims and the restoration of production.

Peer comparison

(No specific peer comparison data provided in the filing.)

Context metrics (time-bound)

  • Revenue FY26: ₹147.58 crore (vs. ₹97.52 crore in FY25)
  • Profit FY26: ₹4.52 crore (vs. ₹5.35 crore in FY25)
  • Basic EPS FY26: ₹4.49 (vs. ₹6.94 in FY25)
  • Long-term borrowings (as of Mar 31, 2026): ₹20.73 crore
  • Short-term borrowings (as of Mar 31, 2026): ₹22.27 crore
  • Fire incident loss estimate: ₹9.39 crore

What to track next

Investors should monitor the progress of new subsidiary incorporations, the impact of the fire incident on insurance claims and production, and any further developments regarding the deferred termination of agreements with Astonea One Private Limited. The company's diversification into nutraceuticals and ayurvedic products will also be a key factor for future growth.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.